RSV vaccine development / Ruth A. Karron.

Format:

Video

Author/Creator:

Karron, Ruth A., author.

Language:

English

Subjects (All):

Drug development.

Physical Description:

1 online resource (1 streaming video file (34 min.)) : color, sound

Place of Publication:

London : Henry Stewart Talks Ltd, 2013.

System Details:

video file

Contents:

Introduction

RSV vaccine development

Financial disclosures

Respiratory syncytial virus (RSV)

RSV structure

RSV seasonality

RSV is a global pediatric pathogen

The spectrum of RSV illness in young children

Risk factors for severe RSV disease

Pediatric RSV hospitalizations distribution

RSV also causes illness in the elderly

Goal for RSV vaccines (1)

RSV can reinfect healthy young adults

Goal for RSV vaccines (2)

Vaccine for RSV does not yet exist

Obstacles to RSV vaccine development

Peak of severe RSV disease

Heterogeneous at-risk population (young and old)

Enhanced RSV disease

The formalin inactivated RSV vaccine study results

What do we know about enhanced RSV disease?

Mechanisms of disease enhancement: humoral

Mechanisms of disease enhancement: cellular

Implications for RSV vaccine development

Prophylaxis against RSV disease

Passive prophylaxis

Use of palivizumab

Passive prophylaxis do not replace vaccination

Active prophylaxis: RSV vaccines

Subunit RSV vaccines

RSV F is the primary target for subunit vaccines

Potential target populations for RSV F vaccine

RSV F structure and vaccine development

Novartis postfusion RSV F vaccine

RSV F nanoparticle vaccine

More approaches to RSV vaccine development

Summary: RSV F subunit vaccines

Live RSV vaccines (1)

Live RSV vaccines: advantages and limitations

Live RSV vaccines (2)

Live attenuated (native) RSV vaccines

Attenuating mutations in rA2cp248/404/1030/?SH

Clinical experience with rA2cp248/404/1030/?SH

Current status of rA2cp248/404/1030/?SH

RSV MEDI ?M2-2: a novel rRSV deletion mutant

Summary: live-attenuated rRSV vaccines

Vectored RSV vaccines

Potential advantages of vectored RSV vaccines

MEDI-534: a chimeric rB/HPIV3/RSV F vaccine

MEDI-534: antibody responses

Sendai-vectored RSV vaccine (rSV-RSV-F)

Replication-defective vectors

Other novel technologies

RSV vaccines: what will the next decade bring?

Our goal: to protect infants and children from RSV.

Notes:

Description based on publisher supplied metadata and other sources.

Retrieved April 15, 2024, from https://hstalks.com/bs/2583/.